LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 122

Search options

  1. Article ; Online: When contactin antibodies hit the podocyte: a new neurorenal syndrome.

    Debiec, Hanna / Ronco, Pierre

    Kidney international

    2021  Volume 100, Issue 6, Page(s) 1163–1165

    Abstract: Membranous nephropathy can be associated with various etiologies and antigens. In this issue of Kidney International, Le Quintrec et al. described contactin-1 cell adhesion molecule as a novel target antigen shared by the peripheral nerve and podocyte in ...

    Abstract Membranous nephropathy can be associated with various etiologies and antigens. In this issue of Kidney International, Le Quintrec et al. described contactin-1 cell adhesion molecule as a novel target antigen shared by the peripheral nerve and podocyte in patients with neurological disease and membranous nephropathy.
    MeSH term(s) Antibodies ; Contactins ; Glomerulonephritis, Membranous/drug therapy ; Humans ; Kidney ; Podocytes
    Chemical Substances Antibodies ; Contactins
    Language English
    Publishing date 2021-11-21
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2021.09.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Membranous nephropathy: current understanding of various causes in light of new target antigens.

    Ronco, Pierre / Debiec, Hanna

    Current opinion in nephrology and hypertension

    2021  Volume 30, Issue 3, Page(s) 287–293

    Abstract: Purpose of review: Membranous nephropathy is an autoimmune disease caused by antibodies mostly directed to podocyte antigens. PLA2R and THSD7A antigens were described in 2009 and 2014 using classical immunochemical techniques. In the last 2 years, ... ...

    Abstract Purpose of review: Membranous nephropathy is an autoimmune disease caused by antibodies mostly directed to podocyte antigens. PLA2R and THSD7A antigens were described in 2009 and 2014 using classical immunochemical techniques. In the last 2 years, thanks to the combination of laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, several antigens associated with various causes have been described in patients with membranous nephropathy. The purpose of this review is to report on those "new" antigens and to analyse the clinicopathological correlations that make each of this antigen unique.
    Recent findings: This article covers the literature of the last 2 years devoted to the description of those new antigens and biomarkers including NELL-1 and Semaphorin 3B in primary membranous nephropathy, and exostosins 1 and 2 and NCAM in lupus class V membranous nephropathy, which will be compared with the previously described antigens. These findings will lead to propose a new classification of membranous nephropathy based on serology and tissue antigen identification that could/should substitute for the classical distinction between primary and secondary membranous nephropathy.
    Summary: The discovery of the latest antigens has major implications for the care of patients with membranous nephropathy as they drive the etiologic investigations and provide invaluable markers for treatment monitoring.
    MeSH term(s) Antigens ; Glomerulonephritis, Membranous/diagnosis ; Glomerulonephritis, Membranous/immunology ; Humans ; Podocytes/immunology ; Podocytes/pathology
    Chemical Substances Antigens
    Language English
    Publishing date 2021-01-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1151092-4
    ISSN 1473-6543 ; 1535-3842 ; 1062-4813 ; 1062-4821
    ISSN (online) 1473-6543 ; 1535-3842
    ISSN 1062-4813 ; 1062-4821
    DOI 10.1097/MNH.0000000000000697
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.

    Conversano, Ester / Debiec, Hanna / Colucci, Manuela / Emma, Francesco / Ronco, Pierre / Vivarelli, Marina

    Pediatric nephrology (Berlin, Germany)

    2023  Volume 39, Issue 1, Page(s) 305–308

    Abstract: Background: Membranous nephropathy is a glomerular disease characterized by the presence of immune-complexes deposited in the subepithelial space of the glomerular basement membrane. It is the main cause of nephrotic syndrome in adults, while in ... ...

    Abstract Background: Membranous nephropathy is a glomerular disease characterized by the presence of immune-complexes deposited in the subepithelial space of the glomerular basement membrane. It is the main cause of nephrotic syndrome in adults, while in children it is very infrequent. Anti-CD20 monoclonal antibodies, mainly rituximab, represent a specific treatment for this disease.
    Case report: We report the case of a child presenting at 2 years of age with steroid-resistant nephrotic syndrome diagnosed upon kidney biopsy as semaphorin 3B (SEMA3B)-associated primary membranous nephropathy. The patient responded to treatment with cyclosporine, but invariably relapsed upon tapering of this agent. Therefore, at age 9, he was successfully treated with rituximab to overcome cyclosporine dependence. However, after the second rituximab infusion, a rapid reconstitution of CD19 + B cells and a relapse of proteinuria occurred, requiring reintroduction of cyclosporine. Obinutuzumab, a type II anti-CD20 monoclonal antibody, was then infused inducing prolonged CD19 + B cell depletion and remission of proteinuria despite discontinuation of cyclosporine. A greater reduction in circulating anti-SEMA3B antibodies assessed by Western blot was observed after obinutuzumab compared with rituximab infusion.
    Discussion: Obinutuzumab was safe and well-tolerated, and may therefore represent an effective therapeutic alternative in children with primary MN and rituximab resistance.
    MeSH term(s) Humans ; Male ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Cyclosporine/therapeutic use ; Glomerulonephritis, Membranous/pathology ; Nephrotic Syndrome/etiology ; Nephrotic Syndrome/complications ; Proteinuria/drug therapy ; Rituximab/therapeutic use ; Semaphorins/therapeutic use ; Child, Preschool
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Cyclosporine (83HN0GTJ6D) ; obinutuzumab (O43472U9X8) ; Rituximab (4F4X42SYQ6) ; Semaphorins
    Language English
    Publishing date 2023-07-19
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ZDB-ID 631932-4
    ISSN 1432-198X ; 0931-041X
    ISSN (online) 1432-198X
    ISSN 0931-041X
    DOI 10.1007/s00467-023-06085-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Molecular Pathogenesis of Membranous Nephropathy.

    Ronco, Pierre / Debiec, Hanna

    Annual review of pathology

    2019  Volume 15, Page(s) 287–313

    Abstract: Membranous nephropathy is a noninflammatory autoimmune disease of the kidney glomerulus, characterized by the formation of immune deposits, complement-mediated proteinuria, and risk of renal failure. Considerable advances in understanding the molecular ... ...

    Abstract Membranous nephropathy is a noninflammatory autoimmune disease of the kidney glomerulus, characterized by the formation of immune deposits, complement-mediated proteinuria, and risk of renal failure. Considerable advances in understanding the molecular pathogenesis have occurred with the identification of several antigens [neutral endopeptidase, phospholipase A2 receptor (PLA
    MeSH term(s) Adult ; Autoantibodies/blood ; Biomarkers/blood ; Disease Progression ; Genetic Predisposition to Disease ; Glomerulonephritis, Membranous/genetics ; Glomerulonephritis, Membranous/immunology ; Glomerulonephritis, Membranous/pathology ; HLA Antigens/genetics ; HLA Antigens/immunology ; Humans ; Infant, Newborn ; Neprilysin/immunology ; Neprilysin/metabolism ; Receptors, Phospholipase A2/immunology ; Receptors, Phospholipase A2/metabolism ; Risk Factors ; Thrombospondins/immunology ; Thrombospondins/metabolism
    Chemical Substances Autoantibodies ; Biomarkers ; HLA Antigens ; Receptors, Phospholipase A2 ; THSD7A protein, human ; Thrombospondins ; Neprilysin (EC 3.4.24.11)
    Language English
    Publishing date 2019-10-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2227429-7
    ISSN 1553-4014 ; 1553-4006
    ISSN (online) 1553-4014
    ISSN 1553-4006
    DOI 10.1146/annurev-pathol-020117-043811
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The role of PLA2R antibody monitoring: what we know and what we do not know.

    Ronco, Pierre / Plaisier, Emmanuelle / Debiec, Hanna

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2021  Volume 38, Issue 4, Page(s) 826–833

    Abstract: For a long time, kidney biopsy was the only diagnostic means for membranous nephropathy (MN) and proteinuria and serum creatinine were the only markers of disease activity. The discovery of the phospholipase A2 receptor (PLA2R) antibody in 2009 has ... ...

    Abstract For a long time, kidney biopsy was the only diagnostic means for membranous nephropathy (MN) and proteinuria and serum creatinine were the only markers of disease activity. The discovery of the phospholipase A2 receptor (PLA2R) antibody in 2009 has induced a paradigm shift in both the diagnosis and monitoring of patients. Two serological tests are routinely used: the enzyme-linked immunosorbent assay (ELISA), which is quantitative, and the immunofluorescence assay (IFA), which is more sensitive. In centres where the two assays are available, the recommendation is to use IFA for screening and diagnosis of immunological remission and ELISA for monitoring the effectiveness of therapy. In patients with positive PLA2R antibody serology, normal kidney function and no evidence of an underlying disease, a kidney biopsy is not mandatory given the almost 100% specificity of the assays. Because MN has different phases, one cannot base a clinical or therapeutic decision on a single measurement of PLA2R antibody at baseline. Risk evaluation of disease progression is a dynamic process that should be performed repeatedly to capture the trajectory of the disease based on both the traditional biomarkers (proteinuria and serum creatinine) and PLA2R antibody levels. The effectiveness of therapy is also evaluated on the PLA2R antibody trajectory, particularly during the first 6 months. Finally, PLA2R antibody monitoring has transformed the management of patients with kidney allografts. Future studies are needed to develop more subtle immunological tests, including monitoring of antigen-specific memory B cells.
    MeSH term(s) Humans ; Receptors, Phospholipase A2 ; Creatinine ; Autoantibodies ; Kidney/pathology ; Glomerulonephritis, Membranous/pathology ; Proteinuria/pathology ; Biomarkers
    Chemical Substances Receptors, Phospholipase A2 ; Creatinine (AYI8EX34EU) ; Autoantibodies ; Biomarkers
    Language English
    Publishing date 2021-12-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfab356
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Advances in Membranous Nephropathy.

    Ronco, Pierre / Plaisier, Emmanuelle / Debiec, Hanna

    Journal of clinical medicine

    2021  Volume 10, Issue 4

    Abstract: Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and ... ...

    Abstract Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure. This review is focused on the recent therapeutic and pathophysiological advances that occurred in the last two years. For a long time, we were lacking a head-to-head comparison between cyclophosphamide considered as the gold standard therapy and other medications, notably rituximab. Substantial progress has been achieved owing to three randomized controlled trials. MENTOR (Membranous Nephropathy Trial of Rituximab) and STARMEN (Sequential Therapy with Tacrolimus and Rituximab in Primary Membranous Nephropathy) conclusively established that calcineurin inhibitor-based regimens are slower to result in an immunologic response than rituximab or cyclophosphamide, achieve fewer complete clinical remissions, and are less likely to maintainremission. Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO) suggested that competition between cyclophosphamide and rituximab remains open. Given the technological leap combining laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, four "new antigens" were discovered including NELL-1 and Semaphorin 3B in so-called primary MN, and exostosins 1 and 2 and NCAM 1 in lupus MN. NELL-1 is associated with about 8% of primary MN and is characterized by segmental immune deposits and frequent association with cancer (30%). Semaphorin 3B-associated MN usually occurs in children, often below the age of two years, where it is the main antigen, representing about 16% of non-lupus MN in childhood. Exostosins 1/2 and NCAM 1 are associated with 30% and 6% of lupus MN, respectively. Exostosins 1/2 (EXT1/2) staining is associated with a low rate of end-stage kidney disease (ESKD) even in mixed classes III/IV+V. These findings already lead to revisiting the diagnostic and therapeutic algorithms toward more personalized medicine.
    Language English
    Publishing date 2021-02-05
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10040607
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cubilin and amnionless protein are novel target antigens in anti-brush border antibody disease.

    Morelle, Johann / Caza, Tiffany / Debiec, Hanna / Aydin, Selda / Storey, Aaron / Ronco, Pierre / Larsen, Christopher

    Kidney international

    2022  Volume 101, Issue 5, Page(s) 1063–1068

    MeSH term(s) Kidney Tubules, Proximal/metabolism ; Receptors, Cell Surface/metabolism
    Chemical Substances Receptors, Cell Surface ; intrinsic factor-cobalamin receptor
    Language English
    Publishing date 2022-03-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2022.02.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.

    Plaisier, Emmanuelle / Not, Adeline / Buob, David / Ronco, Pierre / Debiec, Hanna

    Kidney international

    2021  Volume 100, Issue 6, Page(s) 1342–1344

    MeSH term(s) Contactin 1 ; Glomerulonephritis, Membranous/diagnosis ; Glomerulonephritis, Membranous/drug therapy ; Humans ; Immunologic Factors/therapeutic use ; Receptors, Phospholipase A2 ; Rituximab/therapeutic use
    Chemical Substances Contactin 1 ; Immunologic Factors ; Receptors, Phospholipase A2 ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2021-11-21
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2021.08.029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Advances in Membranous Nephropathy

    Pierre Ronco / Emmanuelle Plaisier / Hanna Debiec

    Journal of Clinical Medicine, Vol 10, Iss 4, p

    2021  Volume 607

    Abstract: Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and ... ...

    Abstract Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure. This review is focused on the recent therapeutic and pathophysiological advances that occurred in the last two years. For a long time, we were lacking a head-to-head comparison between cyclophosphamide considered as the gold standard therapy and other medications, notably rituximab. Substantial progress has been achieved owing to three randomized controlled trials. MENTOR (Membranous Nephropathy Trial of Rituximab) and STARMEN (Sequential Therapy with Tacrolimus and Rituximab in Primary Membranous Nephropathy) conclusively established that calcineurin inhibitor-based regimens are slower to result in an immunologic response than rituximab or cyclophosphamide, achieve fewer complete clinical remissions, and are less likely to maintainremission. Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO) suggested that competition between cyclophosphamide and rituximab remains open. Given the technological leap combining laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, four “new antigens” were discovered including NELL-1 and Semaphorin 3B in so-called primary MN, and exostosins 1 and 2 and NCAM 1 in lupus MN. NELL-1 is associated with about 8% of primary MN and is characterized by segmental immune deposits and frequent association with cancer (30%). Semaphorin 3B-associated MN usually occurs in children, often below the age of two years, where it is the main antigen, representing about 16% of non-lupus MN in childhood. Exostosins 1/2 and NCAM 1 are associated with 30% and 6% of lupus MN, respectively. Exostosins 1/2 (EXT1/2) staining ...
    Keywords membranous nephropathy ; randomized controlled trials ; rituximab ; KDIGO recommendations ; PLA2R ; THSD7A ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-02-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.

    Ronco, Pierre / Debiec, Hanna

    Pflugers Archiv : European journal of physiology

    2017  Volume 469, Issue 7-8, Page(s) 997–1005

    Abstract: Membranous nephropathy (MN) is characterized by an accumulation of immune deposits on the subepithelial side of the glomerular basement membrane, which results in complement activation and proteinuria. Since 2002, several major antigens of the podocyte ... ...

    Abstract Membranous nephropathy (MN) is characterized by an accumulation of immune deposits on the subepithelial side of the glomerular basement membrane, which results in complement activation and proteinuria. Since 2002, several major antigens of the podocyte have been identified in human MN, the first one being neutral endopeptidase (NEP), the alloantigen involved in neonatal cases of MN that occur in newborns from NEP-deficient mothers. This discovery opened the field to the major advances that have occurred since then in the pathophysiology and treatment of MN. It is remarkable that experimental models such as Heymann nephritis and cationic bovine serum albumin-induced MN in the rabbit predicted the pathomechanisms of the human glomerulopathy. The podocyte is at the center of the pathogenesis of MN either by providing a source of endogenous antigens or by creating an environment favorable to deposition and accumulation of immune complexes containing exogenous (non-podocyte) antigens. The podocyte is also a victim of complement activation and antibody blocking activity against enzymes or receptors. A search for innovative drugs aimed at protecting this cell against complement activation and the effects of prolonged ER stress has become a priority.
    Language English
    Publishing date 2017-08
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 6380-0
    ISSN 1432-2013 ; 0031-6768
    ISSN (online) 1432-2013
    ISSN 0031-6768
    DOI 10.1007/s00424-017-2007-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top